CO6241119A2 - Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer - Google Patents

Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer

Info

Publication number
CO6241119A2
CO6241119A2 CO09126919A CO09126919A CO6241119A2 CO 6241119 A2 CO6241119 A2 CO 6241119A2 CO 09126919 A CO09126919 A CO 09126919A CO 09126919 A CO09126919 A CO 09126919A CO 6241119 A2 CO6241119 A2 CO 6241119A2
Authority
CO
Colombia
Prior art keywords
optionally
heterocycloalkyl
optionally substituted
additionally
alkyl
Prior art date
Application number
CO09126919A
Other languages
English (en)
Spanish (es)
Inventor
Chris A Buhr
Longcheng Wang
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CO6241119A2 publication Critical patent/CO6241119A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO09126919A 2007-04-11 2009-11-09 Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer CO6241119A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11

Publications (1)

Publication Number Publication Date
CO6241119A2 true CO6241119A2 (es) 2011-01-20

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09126919A CO6241119A2 (es) 2007-04-11 2009-11-09 Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer

Country Status (25)

Country Link
US (2) US20100209340A1 (enExample)
EP (1) EP2142544B8 (enExample)
JP (1) JP2010523681A (enExample)
KR (1) KR20090130104A (enExample)
CN (1) CN101711249A (enExample)
AU (1) AU2008239596B2 (enExample)
BR (1) BRPI0810175A2 (enExample)
CA (1) CA2683820A1 (enExample)
CO (1) CO6241119A2 (enExample)
CR (1) CR11098A (enExample)
DO (1) DOP2009000242A (enExample)
EA (1) EA018964B1 (enExample)
EC (1) ECSP099722A (enExample)
ES (1) ES2425068T3 (enExample)
IL (1) IL201209A0 (enExample)
MA (1) MA31336B1 (enExample)
MX (1) MX2009010815A (enExample)
MY (1) MY150747A (enExample)
NI (1) NI200900183A (enExample)
NZ (1) NZ579945A (enExample)
SV (1) SV2009003389A (enExample)
TN (1) TN2009000389A1 (enExample)
UA (1) UA101315C2 (enExample)
WO (1) WO2008127712A1 (enExample)
ZA (1) ZA200906648B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767687B2 (en) * 2004-12-13 2010-08-03 Biogen Idec Ma Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
HRP20140975T1 (hr) * 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
CA2663401C (en) * 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
PT2139484E (pt) 2007-04-10 2013-10-31 Exelixis Inc Métodos de tratamento de cancro usando inibidores piridopirimidinona de pi3k-alfa
AU2008239655B2 (en) * 2007-04-11 2013-06-20 Exelixis, Inc. Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer
TW201018685A (en) * 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
RU2573569C2 (ru) * 2009-12-22 2016-01-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
UY33221A (es) 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
TWI642670B (zh) 2010-09-14 2018-12-01 伊塞利克斯公司 Pi3k-德爾塔抑制劑以及其應用和生產方法
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
SG11201401961UA (en) 2011-11-01 2014-05-29 Exelixis Inc N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
PT1940839E (pt) * 2005-10-07 2013-10-10 Exelixis Inc Inibidores de piridopirimidinona pi3k alfa
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
CA2658725A1 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
CA2663401C (en) * 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors

Also Published As

Publication number Publication date
CR11098A (es) 2010-01-27
DOP2009000242A (es) 2010-04-30
MY150747A (en) 2014-02-28
AU2008239596A1 (en) 2008-10-23
US20100209340A1 (en) 2010-08-19
US20130343988A1 (en) 2013-12-26
BRPI0810175A2 (pt) 2014-12-30
EA018964B1 (ru) 2013-12-30
AU2008239596B2 (en) 2013-08-15
KR20090130104A (ko) 2009-12-17
IL201209A0 (en) 2010-05-31
EP2142544B1 (en) 2013-05-22
CN101711249A (zh) 2010-05-19
HK1139941A1 (en) 2010-09-30
NI200900183A (es) 2010-10-05
ECSP099722A (es) 2009-12-28
EP2142544A1 (en) 2010-01-13
ES2425068T3 (es) 2013-10-11
SV2009003389A (es) 2010-04-27
MX2009010815A (es) 2009-10-29
ZA200906648B (en) 2010-04-28
CA2683820A1 (en) 2008-10-23
EP2142544B8 (en) 2013-07-03
JP2010523681A (ja) 2010-07-15
EA200970936A1 (ru) 2010-02-26
TN2009000389A1 (en) 2010-12-31
MA31336B1 (fr) 2010-04-01
WO2008127712A1 (en) 2008-10-23
NZ579945A (en) 2012-05-25
UA101315C2 (ru) 2013-03-25

Similar Documents

Publication Publication Date Title
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
PE20130155A1 (es) Derivados de ariletinilo
ES2722409T3 (es) Moduladores de ROR gamma (RORy)
AR083169A1 (es) Compuestos para tratar enfermedades neurodegenerativas
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
MX344669B (es) Agente antiplaquetas novedoso.
AR066659A1 (es) Derivados de espiroindolinona
UY33430A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
NI201400099A (es) Composición para el control de plagas que incluye un derivado de iminopiridina novedoso
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
CO6241101A2 (es) Derivados de quinolina como inhibidores de la p13 quinasa
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
AR080151A1 (es) Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
AR084913A1 (es) Derivados de aril-benzocicloalquil-amida
PE20151281A1 (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3
PE20060583A1 (es) Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas
AR084606A1 (es) Derivados de biaril-amida
PE20110213A1 (es) Derivados de indolinona como inhibidores de quinasa
AR086024A1 (es) Derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina carboxamidas
ECSP13012990A (es) Derivados de pirazolidin-3-ona
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN

Legal Events

Date Code Title Description
FC Application refused